ENDRA director Harsh gets 60,324 RSUs
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026.
Rhea-AI Filing Summary
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 60,324 | $0.00 | $0.00 |
Footnotes (2)
- F1. Holdings include unvested restricted stock units ("RSUs").
- F2. Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did NDRA director Michael Harsh report?
Director Michael Harsh reported the acquisition of 60,324 shares of ENDRA Life Sciences common stock on January 21, 2026, recorded as an equity award at $0 per share.
When do Michael Harsh’s NDRA RSUs vest?
The filing states that these RSUs will vest in full on January 21, 2026, at which time they convert into ENDRA Life Sciences common stock on a one-for-one basis.
Is Michael Harsh a director or officer of ENDRA Life Sciences (NDRA)?
The Form 4 identifies Michael Harsh as a director of ENDRA Life Sciences Inc. and not as an officer or 10% owner.
AI-generated analysis. How Rhea-AI works. Not financial advice.